Ascendis Pharma A/S (ASND)
USD 135.7
(-3.28%)
USD 135.7
(-3.28%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -467.36 Million | -495.69 Million | -417.64 Million | -271.54 Million | -175.93 Million | -138.8 Million |
| Net Income | -481.44 Million | -583.19 Million | -383.57 Million | -418.95 Million | -218.01 Million | -130.09 Million |
| Depreciation & Amortization | 18.91 Million | 17.95 Million | 15.39 Million | 9.44 Million | 6.68 Million | 880 Thousand |
| Deferred income taxes | 7.3 Million | 5.37 Million | -367 Thousand | -219 Thousand | -234 Thousand | -394 Thousand |
| Stock-based compensation | 66.66 Million | 64.18 Million | 66.83 Million | 53.17 Million | 37.48 Million | 19.65 Million |
| Change in working capital | -99.78 Million | -18.61 Million | -48.91 Million | -964 Thousand | 4.07 Million | 1.7 Million |
| Other non-cash items | 20.99 Million | 18.59 Million | -67.01 Million | 85.97 Million | -5.93 Million | -30.54 Million |
| Investing Cash Flow | 286.47 Million | 61.73 Million | -110.57 Million | -291.19 Million | -5.15 Million | -2.64 Million |
| Investments in PPE | -2.44 Million | -14.48 Million | -24.23 Million | -21.55 Million | -5.15 Million | -2.64 Million |
| Acquisitions | 49.95 Thousand | 9.36 Million | -10.18 Million | 1.69 Million | - | - |
| Investment purchases | -49.95 Thousand | -213.84 Million | -226.03 Million | -537.75 Million | - | - |
| Sales/Maturities of investments | 288.86 Million | 280.52 Million | 149.88 Million | 263.05 Million | - | - |
| Other Investing Activities | 51 Thousand | 171.72 Thousand | -86.87 Million | 3.36 Million | - | - |
| Financing Cash Flow | 134.29 Million | 396.77 Million | 351.38 Million | 602.65 Million | 493.59 Million | 203.26 Million |
| Debt repayment | -10.43 Million | -496.92 Million | -6.42 Million | -4.77 Million | -4.03 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -1.81 Million | -105.3 Million | -21.6 Million | - | - | - |
| Common Stock Issuance | 10.07 Million | 5.06 Million | 367.88 Million | 638.79 Million | 529.33 Million | 216.38 Million |
| Other Financing Activities | 134.65 Million | 5.15 Million | 44.67 Million | -31.37 Million | -31.7 Million | -13.11 Million |
| Accounts receivables | -32.1 Million | -11.32 Million | -6.92 Million | -1.85 Million | -1.87 Million | 182 Thousand |
| Accounts payables | 3.47 Million | 45.11 Million | 40.74 Million | 7.34 Million | 7.5 Million | 8.26 Million |
| Inventory | -78.25 Million | -55.26 Million | -75.4 Million | -5.48 Million | -5.63 Million | - |
| Other working capital | 7.09 Million | 2.85 Million | -7.33 Million | -964 Thousand | 4.07 Million | -6.73 Million |
| Cash at beginning of period | 444.76 Million | 446.26 Million | 584.51 Million | 598.1 Million | 277.86 Million | 195.35 Million |
| Cash at end of period | 392.16 Million | 444.76 Million | 446.26 Million | 584.51 Million | 598.1 Million | 277.86 Million |
| Capital Expenditure | -2.44 Million | -14.48 Million | -24.23 Million | -21.55 Million | -5.15 Million | -2.64 Million |
| Effect of forex changes on cash | -6 Million | 35.69 Million | 38.59 Million | -53.49 Million | 7.74 Million | 20.69 Million |
| Net cash flow / Change in cash | -52.6 Million | -1.5 Million | -138.25 Million | -13.58 Million | 320.24 Million | 82.51 Million |
| Free Cash Flow | -469.8 Million | -510.18 Million | -441.88 Million | -293.1 Million | -181.09 Million | -141.45 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -109.38 Million | -131.03 Million | -86.87 Million | -481.44 Million | -162.22 Million | -121.43 Million |
| Depreciation & Amortization | 4.38 Million | 4.47 Million | 4.97 Million | 18.91 Million | 4.74 Million | 4.64 Million |
| Deferred income taxes | - | 2.5 Million | 5.79 Million | 7.3 Million | 645 Thousand | -429 Thousand |
| Stock-based compensation | 26 Million | 17.28 Million | 15.9 Million | 66.66 Million | 17.18 Million | 19.88 Million |
| Change in working capital | -24.2 Million | -51.83 Million | -15.21 Million | -99.78 Million | -24.03 Million | -34.56 Million |
| Other non-cash items | 41.89 Million | 48.81 Million | 32.94 Million | 20.99 Million | 38.96 Million | -21.23 Million |
| Investing Cash Flow | 608 Thousand | 7.15 Million | 6.65 Million | 286.47 Million | 22.22 Million | 46.95 Million |
| Investments in PPE | -342 Thousand | -199 Thousand | 63 Thousand | -2.44 Million | -976 Thousand | -444 Thousand |
| Acquisitions | 957.94 Thousand | - | 4284.28 | 49.95 Thousand | 47.34 Thousand | - |
| Investment purchases | - | - | -4284.28 | -49.95 Thousand | -47.34 Thousand | - |
| Sales/Maturities of investments | -36.18 Thousand | 7.35 Million | 6.58 Million | 288.86 Million | 23.15 Million | 47.4 Million |
| Other Investing Activities | 950 Thousand | 7.35 Million | 5000.00 | 51 Thousand | 46 Thousand | 47.4 Million |
| Financing Cash Flow | -2.45 Million | 18.42 Million | -6.05 Million | 134.29 Million | 143.35 Million | -2.3 Million |
| Debt repayment | -2.82 Million | -2.78 Million | -2.73 Million | -10.43 Million | -2.61 Million | -2.51 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -1.81 Million | -1.81 Million | - | - |
| Common Stock Issuance | 263.7 Thousand | 21.33 Million | 1.85 Million | 10.07 Million | 6.38 Million | 224.73 Thousand |
| Other Financing Activities | 365 Thousand | 21.2 Million | -5.17 Million | 134.65 Million | 139.59 Million | -16.73 Thousand |
| Accounts receivables | -11.46 Million | -11.28 Million | -7.98 Million | -32.1 Million | -13.97 Million | -1.19 Million |
| Accounts payables | 8.61 Million | -19.13 Million | -9.95 Million | 3.47 Million | 4.45 Million | -4.74 Million |
| Inventory | -18.51 Million | -23.75 Million | -19.79 Million | -78.25 Million | -21.21 Million | -17.06 Million |
| Other working capital | 5.77 Million | 6.12 Million | 22.52 Million | 7.09 Million | 6.7 Million | -11.54 Million |
| Cash at beginning of period | 320.23 Million | 392.16 Million | 441.26 Million | 444.76 Million | 394.22 Million | 501.28 Million |
| Cash at end of period | 258.69 Million | 320.23 Million | 392.16 Million | 392.16 Million | 441.26 Million | 394.22 Million |
| Capital Expenditure | -342 Thousand | -199 Thousand | 63 Thousand | -2.44 Million | -976 Thousand | -444 Thousand |
| Effect of forex changes on cash | 1.61 Million | 4.07 Million | -7.23 Million | -6 Million | 6.18 Million | 1.42 Million |
| Net cash flow / Change in cash | -61.54 Million | -71.92 Million | -49.1 Million | -52.6 Million | 47.04 Million | -107.05 Million |
| Free Cash Flow | -61.65 Million | -101.78 Million | -42.4 Million | -469.8 Million | -125.69 Million | -153.57 Million |
0859
LLFICL
ADVM
IFCI
BESTAGRO
INCREDIBLE